: X-linked acrogigantism (X-LAG) is a rare form of pituitary gigantism that is associated with growth hormone (GH) and prolactin-secreting pituitary adenomas/pituitary neuroendocrine tumors (PitNETs) that develop in infancy. It is caused by a duplication on chromosome Xq26.3 that leads to the misexpression of the gene GPR101, a constitutively active stimulator of pituitary GH and prolactin secretion. GPR101 normally exists within its own topologically associating domain (TAD) and is insulated from surrounding regulatory elements. X-LAG is a TADopathy in which the duplication disrupts a conserved TAD border, leading to a neo-TAD in which ectopic enhancers drive GPR101 over-expression, thus causing gigantism. Here we trace the full diagnostic and therapeutic pathway of a female patient with X-LAG from 4C-seq studies demonstrating the neo-TAD through medical and surgical interventions and detailed tumor histopathology. The complex nature of treating young children with X-LAG is illustrated, including the achievement of hormonal control using a combination of neurosurgery and adult doses of first-generation somatostatin analogs.

Caruso, M., Mazzatenta, D., Asioli, S., Costanza, G., Trivellin, G., Franke, M., et al. (2024). Case report: Management of pediatric gigantism caused by the TADopathy, X-linked acrogigantism. FRONTIERS IN ENDOCRINOLOGY, 15, 1-9 [10.3389/fendo.2024.1345363].

Case report: Management of pediatric gigantism caused by the TADopathy, X-linked acrogigantism

Mazzatenta, Diego;Asioli, Sofia;
2024

Abstract

: X-linked acrogigantism (X-LAG) is a rare form of pituitary gigantism that is associated with growth hormone (GH) and prolactin-secreting pituitary adenomas/pituitary neuroendocrine tumors (PitNETs) that develop in infancy. It is caused by a duplication on chromosome Xq26.3 that leads to the misexpression of the gene GPR101, a constitutively active stimulator of pituitary GH and prolactin secretion. GPR101 normally exists within its own topologically associating domain (TAD) and is insulated from surrounding regulatory elements. X-LAG is a TADopathy in which the duplication disrupts a conserved TAD border, leading to a neo-TAD in which ectopic enhancers drive GPR101 over-expression, thus causing gigantism. Here we trace the full diagnostic and therapeutic pathway of a female patient with X-LAG from 4C-seq studies demonstrating the neo-TAD through medical and surgical interventions and detailed tumor histopathology. The complex nature of treating young children with X-LAG is illustrated, including the achievement of hormonal control using a combination of neurosurgery and adult doses of first-generation somatostatin analogs.
2024
Caruso, M., Mazzatenta, D., Asioli, S., Costanza, G., Trivellin, G., Franke, M., et al. (2024). Case report: Management of pediatric gigantism caused by the TADopathy, X-linked acrogigantism. FRONTIERS IN ENDOCRINOLOGY, 15, 1-9 [10.3389/fendo.2024.1345363].
Caruso, Manuela; Mazzatenta, Diego; Asioli, Sofia; Costanza, Giuseppe; Trivellin, Giampaolo; Franke, Martin; Abboud, Dayana; Hanson, Julien; Raverot, ...espandi
File in questo prodotto:
File Dimensione Formato  
fendo-15-1345363_compressed.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 5.6 MB
Formato Adobe PDF
5.6 MB Adobe PDF Visualizza/Apri
Image 1.pdf

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per accesso libero gratuito
Dimensione 96.51 kB
Formato Adobe PDF
96.51 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/1005627
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact